Nektar Therapeutics (NKTR) Highlights Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. MU
2. SPCX
3. APTX:CN
4. SPY
5. IQMX
6. EROC
7. MSTR
8. NVDA
9. RIVN
10. TSLA

Go back to Nektar Therapeutics (NKTR) Highlights Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358

Nektar Therapeutics (NKTR) PT Raised to $20 at Oppenheimer

November 7, 2019 10:24 AM EST

Oppenheimer analyst Jay Olson raised the price target on Nektar Therapeutics (NASDAQ: NKTR) to $20.00 (from $18.00) while maintaining a Perform rating.

The analyst commented, "Nektar reported 3Q19 financial results, revised 2019 guidance, and provided pipeline updates including multiple catalysts. While NKTR has several promising... More

Nektar Therapeutics (NKTR) PT Lowered to $40 at Cowen

November 7, 2019 8:26 AM EST

Cowen lowered its price target on Nektar Therapeutics (NASDAQ: NKTR) to $40.00 (from $43.00) while maintaining a Outperform rating.... More

Nektar Therapeutics (NKTR) PT Lowered to $35 at Piper Jaffray

November 7, 2019 6:57 AM EST

Piper Jaffray analyst Tyler Van Buren lowered the price target on Nektar Therapeutics (NASDAQ: NKTR) to $35.00 (from $50.00) while maintaining a Overweight rating.... More